Bremelanotide

From Retapedia, the free peptide encyclopedia
Medical disclaimer. This article is for informational purposes only and does not constitute medical advice. Consult a qualified clinician before considering any compound discussed below. See Retapedia : Medical disclaimer.

Bremelanotide is a therapeutically researched peptide studied for its effects on physiological function. Bremelanotide (Vyleesi) is an FDA-approved melanocortin agonist for low sexual desire in premenopausal women; preclinical potential for erectile dysfunction.

Bremelanotide, sold under the brand name Vyleesi, is a medication used to treat low sexual desire in women. Specifically it is used for low sexual desire which occurs before menopause and is not due to medical problems, psychiatric problems, or problems within the relationship. It is given by an injection just under the skin of the thigh or abdomen.

Natty status
Bremelanotide is generally regarded as compatible with natural bodybuilding, though competitive federations may differ. See § Natty status.

Overview

Bremelanotide, sold under the brand name Vyleesi, is a medication used to treat low sexual desire in women. Specifically it is used for low sexual desire which occurs before menopause and is not due to medical problems, psychiatric problems, or problems within the relationship. It is given by an injection just under the skin of the thigh or abdomen.

Mechanism of action

FDA-approved (as Vyleesi) for low sexual desire in premenopausal women. Activates central melanocortin receptors to drive arousal. Shows preclinical promise for erectile dysfunction. Given by subcutaneous injection.

Reported effects

Effects reported in the literature and from preclinical models include:

  • Shows efficacy for erectile dysfunction via central nervous system activation and nitric oxide regulation [1] Preclinical
  • Offers a therapeutic mechanism for erectile dysfunction distinct from PDE5 inhibitors, though large-scale clinical trials are still needed to establish safety and optimal dosing [1] Preclinical

Evidence grades: FDA approved Phase III Phase II Phase I Preclinical Anecdotal

Natty status

Bremelanotide is generally regarded as compatible with the natty designation, particularly when used for therapeutic healing purposes. Opinions vary across natural bodybuilding federations, and athletes who compete should consult the rulebook of their respective sanctioning body.[2]

Research

The peptide has been the subject of 3 studies and reference works collected on this site. The full bibliography is in § External links below.

Other peptides in this catalogue with overlapping mechanisms or status:

References

  1. a b Intravenous peptides and amino acids for erectile dysfunction: a narrative review of current applications and future directions. Recent review
  2. a b World Anti-Doping Agency. (2026). Prohibited List 2026.

External links

Categories: Peptides | Therapeutic peptides |

This page was last updated on July 17, 2026, at 16:24 (UTC).

Research last reviewed on July 17, 2026.

Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply.